Tajikistan Conformity Assessment and Quality Certificates: Batch-by-Batch Control Explained

1. Key takeaways

Tajikistan applies a system of batch-by-batch quality conformity assessment to medicines and medical devices, and issues quality certificates when the assessment is passed. Article 13(1) of Law No. 1893 provides that the quality conformity assessment of medicines and medical devices aims to determine whether a specific batch introduced into the territory or produced in the territory meets the requirements of the quality control normative document, and that on the basis of the assessment result the State Supervisory Authority for Pharmaceutical Activities and its subordinate bodies issue quality certificates to the relevant persons. GRZAN notes that this system runs parallel to national registration: registration targets the product, conformity assessment targets the batch, and holding a registration certificate does not mean that every shipment can be released through customs and into the market.

2. Legal basis

3. Expert insights

Insight 1: registration and conformity assessment are two parallel systems, and this is where companies most often go wrong. Article 17 governs national registration, which targets the product and is valid for five years, while Article 13 governs quality conformity assessment, which targets the batch and proceeds shipment by shipment. GRZAN stresses this point repeatedly to clients: the registration certificate only answers whether the product may enter Tajikistan at all; it does not answer whether this particular shipment can be released. The two stages have their own documents, their own fees and their own timelines, and neither can substitute for the other in any way.

Insight 2: Article 1(44) reveals the special status of the quality control normative document. The definition is a document developed by the manufacturer, establishing comprehensive quality requirements on the basis of expert review and approved by the Ministry of Health jointly with the supervisory authority. Three features stand out: it is drafted by the manufacturer, it passes expert review, and it requires approval by two bodies. This means the quality control document drafted at the registration stage becomes the decision benchmark for every subsequent batch assessment, so the quality of the drafting directly determines the release efficiency of every future shipment over the whole life of the certificate.

Insight 3: Article 13(2) and Article 9(4) together lock down who sets the fees. Article 13(2) assigns the procedure and fee rates for conformity assessment services to the Ministry of Health jointly with the antimonopoly body, while Article 9(4) assigns the fee rates for quality certificates and expert assessment services to the supervisory authority jointly with the antimonopoly body. What both provisions share is participation of the antimonopoly body in pricing, a design aimed at preventing runaway pricing for monopoly services. For companies this means that both fees have a legal pricing document behind them, and the company is entitled to request the formal fee basis in writing.

Insight 4: the issuing body under Article 13(1) is the supervisory authority and its subordinate bodies. The provision makes clear that quality certificates are issued by the supervisory authority and its subordinate bodies, which means the body actually performing the assessment may be a subordinate technical institution. GRZAN recommends identifying the exact subordinate institution handling the case and confirming that the certificate format it issues is accepted by customs posts and by purchasers in tender procedures.

Insight 5: the conformity assessment procedure for parapharmaceuticals is listed separately. The final sentence of Article 13(1) provides that the procedure for the quality conformity assessment of parapharmaceuticals is developed and approved by the Ministry of Health, mirroring the structure of Article 17(12). Companies handling parapharmaceutical products, such as bioactive supplements and therapeutic cosmetics, should therefore request the separate procedural document rather than rely on the medicine or device version.

4. Practical recommendations

1. Manage the registration certificate and batch quality certificates in separate ledgers within the quality system. GRZAN recommends keeping two registers for Tajikistan: one tracking the five-year registration certificate, one tracking the quality certificate of each batch, with expiry dates and responsible persons assigned separately for each.
2. Draft the quality control normative document to decision-benchmark standards. Under Article 1(44), the document is the benchmark for every later batch assessment. Introduce a testability review at the drafting stage, so that no clause is unmeasurable or open to interpretation at release.
3. Request the formal fee basis and compare it item by item. Under Article 13(2) and Article 9(4), require the executing body to produce the fee basis document and reconcile it against the internal budget; do not accept verbal quotations without a documented basis.
4. Confirm the issuing body and the acceptability of its certificate format. Under Article 13(1), identify the exact subordinate institution and confirm that its quality certificates are accepted in customs clearance and in procurement bidding.
5. Quantify the exemption under Article 13(4) against repeated batch costs. Batch assessment is a recurring cost per shipment, while a GMP certificate is a one-time investment; run a quantitative comparison over the annual batch volume to locate the break-even point of the exemption.

5. Verification checklist

• □ Confirmed that registration under Article 17 and conformity assessment under Article 13 are two parallel systems
• □ Set up two separate ledgers for Tajikistan covering the registration certificate and batch quality certificates
• □ Drafted the quality control normative document to decision-benchmark standards under Article 1(44)
• □ Obtained the formal fee basis for conformity assessment and quality certificates under Article 13(2) and Article 9(4)
• □ Confirmed the exact issuing subordinate institution and the acceptability of its certificate format
• □ Quantified the break-even point of the Article 13(4) exemption against the annual batch volume
• □ Requested the separate conformity assessment procedure document for parapharmaceuticals, where applicable

Regulatory information verified as of October 29, 2026.

In the Central Asian market, the core capabilities of GRZAN concentrate on three areas. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a dual-track choice exists between the national route and the Union route; Uzbekistan is an observer state with only a national route; Tajikistan and Turkmenistan sit outside the Union framework and must follow purely national procedures. Second, local authorized representative services: GRZAN acts as the statutory representative of manufacturers in these countries and undertakes registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN helps establish a quality management system conforming to ISO 13485 and connects clients with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com